Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Consensus Rating of "Hold" from Analysts

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) has been assigned an average recommendation of "Hold" from the five brokerages that are currently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $3.67.

A number of equities analysts have weighed in on LXRX shares. Wall Street Zen started coverage on Lexicon Pharmaceuticals in a research report on Monday, April 21st. They set a "sell" rating for the company. HC Wainwright reaffirmed a "buy" rating and set a $4.00 price target on shares of Lexicon Pharmaceuticals in a research report on Tuesday, June 24th.

Lexicon Pharmaceuticals Trading Down 4.4%

Shares of Lexicon Pharmaceuticals stock traded down $0.05 during trading on Thursday, hitting $1.08. 3,257,403 shares of the company were exchanged, compared to its average volume of 6,886,740. The firm has a market capitalization of $390.41 million, a P/E ratio of -2.12 and a beta of 1.13. Lexicon Pharmaceuticals has a 1-year low of $0.28 and a 1-year high of $2.45. The firm's fifty day moving average price is $0.74 and its 200 day moving average price is $0.66. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.22 and a quick ratio of 2.22.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last posted its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.03. Lexicon Pharmaceuticals had a negative return on equity of 103.16% and a negative net margin of 568.04%. The company had revenue of $1.26 million during the quarter, compared to analyst estimates of $1.26 million. As a group, sell-side analysts expect that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current fiscal year.

Institutional Trading of Lexicon Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Point72 Asset Management L.P. lifted its stake in shares of Lexicon Pharmaceuticals by 630.7% in the fourth quarter. Point72 Asset Management L.P. now owns 8,988,421 shares of the biopharmaceutical company's stock worth $6,638,000 after acquiring an additional 7,758,371 shares during the period. Schonfeld Strategic Advisors LLC lifted its stake in shares of Lexicon Pharmaceuticals by 301.5% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 7,558,621 shares of the biopharmaceutical company's stock worth $5,582,000 after acquiring an additional 5,676,021 shares during the period. Nantahala Capital Management LLC lifted its stake in shares of Lexicon Pharmaceuticals by 186.6% in the fourth quarter. Nantahala Capital Management LLC now owns 6,604,150 shares of the biopharmaceutical company's stock worth $4,877,000 after acquiring an additional 4,300,000 shares during the period. AQR Capital Management LLC acquired a new position in shares of Lexicon Pharmaceuticals in the first quarter worth approximately $541,000. Finally, Tang Capital Management LLC lifted its stake in shares of Lexicon Pharmaceuticals by 750.3% in the fourth quarter. Tang Capital Management LLC now owns 850,268 shares of the biopharmaceutical company's stock worth $628,000 after acquiring an additional 750,268 shares during the period. 74.70% of the stock is currently owned by institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.